Literature DB >> 25298192

Targeting receptor tyrosine kinases and their downstream signaling with cell-penetrating peptides in human pulmonary artery smooth muscle and endothelial cells.

Jun Yu1, Chamila Rupasinghe, Jamie L Wilson, Linda Taylor, Nader Rahimi, Dale Mierke, Peter Polgar.   

Abstract

Cell-penetrating peptide (CPP) intracellular delivery of receptor signaling motifs provides an opportunity to regulate specific receptor tyrosine kinase signal transductions. We targeted tyrosine residues Y740 and Y751 of the PDGF receptor β (PDGFRβ) and Y1175 of the VEGF receptor 2 (VEGFR2). The Y740 and Y751 motifs activated ERK and Akt, while the Y1175 motif activated ERK. Targeting either Y740 or Y751 of the PDGFRβ in human pulmonary artery smooth muscle cells (HPASMC) effectively inhibited PDGF activation of ERK or Akt. Interfering with the Y751 region of the PDGFRβ proved more effective than targeting the Y740 region. The phosphorylation of Y751 of the CPP and the length and exact sequence of the mimicking peptide proved crucial. On the other hand, in human pulmonary artery endothelial cell phosphorylation of the VEGFR2 Y1175 CPP was not a determinant in blockage of ERK activation. Likewise, the length of the peptide mimic was not crucial with a very small sequence containing the Y1175 remaining effective. Physiologic proof of concept for the effectiveness of the CPP was confirmed by blockage of HPASMC migration in response to PDGF following culture injury. Thus targeted blockage of tyrosine kinase receptor signaling can be very effective.
© 2014 John Wiley & Sons A/S.

Entities:  

Keywords:  Akt; ERK; cell-penetrating peptide; drug delivery; human pulmonary artery endothelial cells; human pulmonary artery smooth muscle cells; platelet-derived growth factor receptor β; receptor tyrosine kinases; vascular endothelial growth factor receptor 2

Mesh:

Substances:

Year:  2014        PMID: 25298192      PMCID: PMC4390552          DOI: 10.1111/cbdd.12446

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  26 in total

Review 1.  Protein transduction: unrestricted delivery into all cells?

Authors:  S R Schwarze; K A Hruska; S F Dowdy
Journal:  Trends Cell Biol       Date:  2000-07       Impact factor: 20.808

2.  Studies on the internalization mechanism of cationic cell-penetrating peptides.

Authors:  Guillaume Drin; Sylvine Cottin; Emmanuelle Blanc; Anthony R Rees; Jamal Temsamani
Journal:  J Biol Chem       Date:  2003-06-03       Impact factor: 5.157

Review 3.  VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy.

Authors:  Nader Rahimi
Journal:  Front Biosci       Date:  2006-01-01

4.  Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.

Authors:  C Rousselle; M Smirnova; P Clair; J M Lefauconnier; A Chavanieu; B Calas; J M Scherrmann; J Temsamani
Journal:  J Pharmacol Exp Ther       Date:  2001-01       Impact factor: 4.030

5.  Direct interaction between Shc and the platelet-derived growth factor beta-receptor.

Authors:  K Yokote; S Mori; K Hansen; J McGlade; T Pawson; C H Heldin; L Claesson-Welsh
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

6.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Authors:  Laszlo Farkas; Daniela Farkas; Kjetil Ask; Antje Möller; Jack Gauldie; Peter Margetts; Mark Inman; Martin Kolb
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

7.  A cell permeable peptide targeting the intracellular loop 2 of endothelin B receptor reduces pulmonary hypertension in a hypoxic rat model.

Authors:  Daniel S Green; Chamila Rupasinghe; Rod Warburton; Jamie L Wilson; Christine O Sallum; Linda Taylor; Achani Yatawara; Dale Mierke; Peter Polgar; Nicholas Hill
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

8.  Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.

Authors:  A Kashishian; A Kazlauskas; J A Cooper
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

9.  Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Authors:  Marius M Hoeper; Robyn J Barst; Robert C Bourge; Jeremy Feldman; Adaani E Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M Hassoun; Nicholas W Morrell; Andrew J Peacock; Toru Satoh; Gérald Simonneau; Victor F Tapson; Fernando Torres; David Lawrence; Deborah A Quinn; Hossein-Ardeschir Ghofrani
Journal:  Circulation       Date:  2013-02-12       Impact factor: 29.690

Review 10.  Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics.

Authors:  Frederic Heitz; May Catherine Morris; Gilles Divita
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

View more
  5 in total

1.  Modulating the dysregulated migration of pulmonary arterial hypertensive smooth muscle cells with motif mimicking cell permeable peptides.

Authors:  Jamie L Wilson; Chamila Rupasinghe; Anny Usheva; Rod Warburton; Chloe Kaplan; Linda Taylor; Nicholas Hill; Dale F Mierke; Peter Polgar
Journal:  Curr Top Pept Protein Res       Date:  2015

2.  Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK.

Authors:  Jamie L Wilson; Jun Yu; Linda Taylor; Peter Polgar
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

3.  Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells.

Authors:  Hojjat Bazzazi; Aleksander S Popel
Journal:  PLoS Comput Biol       Date:  2017-02-08       Impact factor: 4.475

4.  Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation.

Authors:  Hojjat Bazzazi; Jeffery S Isenberg; Aleksander S Popel
Journal:  Front Physiol       Date:  2017-02-06       Impact factor: 4.566

Review 5.  Anti-Angiogenic Property of Free Human Oligosaccharides.

Authors:  Boram Bae; Haeun Kim; Hyerin Park; Young Jun Koh; Sung-Jin Bae; Ki-Tae Ha
Journal:  Biomolecules       Date:  2021-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.